A detailed history of Cutler Group LP transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Cutler Group LP holds 386 shares of COGT stock, worth $3,026. This represents 0.0% of its overall portfolio holdings.

Number of Shares
386
Previous 700 44.86%
Holding current value
$3,026
Previous $4,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 19, 2024

SELL
$4.38 - $9.02 $1,375 - $2,832
-314 Reduced 44.86%
386 $2,000
Q4 2023

Jan 18, 2024

BUY
$4.06 - $10.08 $2,841 - $7,056
700 New
700 $4,000
Q1 2023

May 01, 2023

SELL
$10.04 - $15.5 $10,040 - $15,500
-1,000 Reduced 83.33%
200 $2,000
Q4 2022

Feb 07, 2023

SELL
$10.65 - $14.84 $3,344 - $4,659
-314 Reduced 20.74%
1,200 $13,000
Q3 2022

Oct 25, 2022

SELL
$9.39 - $16.99 $56,152 - $101,600
-5,980 Reduced 79.8%
1,514 $22,000
Q2 2022

Aug 04, 2022

BUY
$3.92 - $9.73 $29,376 - $72,916
7,494 New
7,494 $67,000

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $516M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.